Effect of Glucagon-Like Peptide-1 Receptor Agonists on Heart Failure Outcomes and Cardiovascular Death Across Varying Cardiovascular-Kidney-Metabolic Comorbidity

Glucagon-like peptide-1 receptor agonists reduce HFH and CV death across CKM conditions, with generally consistent effects in varying combinations of these diseases. The potential exception is among patients with HFrEF, where a reduction in risk of CV death, but a numeric increase in HFH, was observed. Definitive CV outcome trials are needed to definitively determine effects of GLP-1RAs in patients with established HFrEF.